Mainz Biomed BV (NASDAQ:MYNZ) — Market Cap & Net Worth
Market Cap & Net Worth: Mainz Biomed BV (MYNZ)
Mainz Biomed BV (NASDAQ:MYNZ) has a market capitalization of $9.49 Million ($9.49 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27289 globally and #5644 in its home market, demonstrating a -16.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mainz Biomed BV's stock price $0.76 by its total outstanding shares 12515336 (12.52 Million). Also see Mainz Biomed BV (MYNZ) total assets for a full breakdown of the balance sheet.
Mainz Biomed BV Market Cap History: 2021 to 2026
Mainz Biomed BV's market capitalization history from 2021 to 2026. Data shows change from $130.03 Million to $9.49 Million (-55.80% CAGR). Also see MYNZ cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Mainz Biomed BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #777 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2516 of 3165 |
Weight: Mainz Biomed BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mainz Biomed BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mainz Biomed BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Mainz Biomed BV (MYNZ) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
26.10x
Mainz Biomed BV's market cap is 26.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $130.03 Million | $577.35K | -$11.69 Million | 225.23x | N/A |
| 2022 | $88.86 Million | $529.88K | -$26.45 Million | 167.70x | N/A |
| 2023 | $14.52 Million | $895.48K | -$26.30 Million | 16.21x | N/A |
| 2024 | $54.07 Million | $893.99K | -$21.65 Million | 60.48x | N/A |
| 2025 | $14.02 Million | $537.08K | -$16.21 Million | 26.10x | N/A |
Competitor Companies of MYNZ by Market Capitalization
Companies near Mainz Biomed BV in the global market cap rankings as of September 18, 2026. Review MYNZ goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mainz Biomed BV by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #160 globally with a market cap of $150.10 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #470 globally with a market cap of $58.08 Billion USD ( CN¥396.94 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.32 |
| #160 | Danaher Corporation | NYSE:DHR | $150.10 Billion | $212.50 |
| #470 | WuXi AppTec Co Ltd | SHG:603259 | $58.08 Billion | CN¥160.49 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $366.31 |
Mainz Biomed BV Historical Marketcap From 2021 to 2026
Between 2021 and today, Mainz Biomed BV's market cap moved from $130.03 Million to $ 9.49 Million, with a yearly change of -55.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.49 Million | -32.29% |
| 2025 | $14.02 Million | -74.07% |
| 2024 | $54.07 Million | +272.41% |
| 2023 | $14.52 Million | -83.66% |
| 2022 | $88.86 Million | -31.67% |
| 2021 | $130.03 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Mainz Biomed BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.49 Million USD |
| MoneyControl | $9.49 Million USD |
| MarketWatch | $9.49 Million USD |
| marketcap.company | $9.49 Million USD |
| Reuters | $9.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more